[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-patients-treated-by-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-patients-treated-by-radiotherapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,84,112,141,165,192,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100616055","spaceoar-post-market-registry-study-100616055",false,"NCT07300631","SpaceOAR Post-Market Registry Study","OASIS: SpaceOAR PoSt - Market Registry Study: Assessing the Safety & Acceptability of SpaceOAR Use With Prostate Radiotherapy","OASIS","Inclusion Criteria:\n\n* All patients with a clinical diagnosis of prostate cancer planned to undergo treatment with curative intent at selected sites in the UK \\& France subject to a SpaceOAR being used as usual care.\n* Aged 18 years old or above.\n* Patients who agrees to participate and has been deemed by their medical team to have capacity to provide;\n\n  * verbal, informed consent over telephone as documented on the study informed consent form by the Researchers (UK only)\n  * written, informed consent by signature of the study informed consent form (France only)\n* Patient covered by social security scheme (France only)\n\nExclusion Criteria:\n\n\\- Patients lacking the capacity to provide;\n\n* informed consent as documented on the study informed consent form by the - Researchers (UK only)\n* written, informed consent by signature of the study informed consent form (France only)","MALE","18 Years",{"count":20,"type":21},320,"ESTIMATED","3 Years","OBSERVATIONAL","Recently, concerns have been raised by regulators that there is little data about the long-term safety of rectal hydrogel spacers for use in conjunction with radiotherapy treatment for prostate cancer. To address this, this study will collect data about the short-term side-effects and long-term safety of SpaceOAR and SpaceOAR Vue rectal hydrogel spacers in men who receive them in the UK and France. Men who have agreed to receive these spacers as part of their standard medical care will be asked to take part in the study whereby data about their treatment and health will be collected from their medical records and from members of the clinical team who deliver their treatment. Additionally, men will be asked to consent to completing questionnaires about their experiences of side effects from their treatment. Further information will be collected about their clinical characteristics before they receive a spacer, the physician-rated clinical performance of the spacer insertion procedure, their radiotherapy treatment plan and details of the other treatments they are also receiving which could influence the types and extent of side effects they experience. Data collection will span eight time points: pre-spacer insertion, spacer insertion, the start of radiotherapy, post-radiotherapy follow-up, 6-month follow-up, 12-month follow-up, 24-month follow-up \\& 36-month follow-ups. Outside of these timepoints treatment-related adverse event data will be concurrently reported and collated. Participants' treatments will not be changed as a result of their participation in this study. Data from this study will be used to summarise the characteristics of this study population, physicians' perceptions of the spacer implantation procedure, the radiotherapy treatments plans made, and the types, extent and timing of treatment-related adverse events and side effects.",[26],"Prostate Cancer Patients Treated by Radiotherapy",[28],"rectal spacer","RECRUITING","2026-05-06",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":35,"type":33},"2025-12-31",{"date":37,"type":21},"2030-02",{"name":39,"class":40},"Sheffield Teaching Hospitals NHS Foundation Trust","OTHER",7,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100630230","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-prostate-cancers-in-algeria-100630230","NCT07484971","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","CLIQQC","Inclusion Criteria:\n\n* Patients aged 19 years and older.\n* Diagnosis of prostate cancer confirmed histologically and\u002For biologically.\n* Patients followed in the participating oncology departments.\n* Written informed consent obtained.\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma\n* Secondary tumors\n* Participation in an interventional study","19 Years",{"count":51,"type":21},2000,"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[54,55,56,26,57,58],"Prostate Cancer","Prostate Cancer (Diagnosis)","Prostate Cancer (Post Prostatectomy)","Prostate Cancer Metastatic","Prostate Cancer (Adenocarcinoma)",[60,61,54,62,63,64,65,66,67,68,69,70,71,72,73],"oncology","patient outcome","Prostate Cancer in Algerian patients","Observational Study","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study","Real-world data","Algeria","Algerian Study","2026-04-14",{"date":76,"type":33},"2026-04-17",{"date":78,"type":33},"2025-07-21",{"date":80,"type":21},"2026-07-21",{"name":82,"class":40},"Société Algérienne de Formation et Recherche en Oncologie",24,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100618467","phase-2-a-biomarker-study-in-men-with-localized-prostate-cancer-treated-with-aglatimagene-besadenovec-100618467","NCT07332000","A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec","Inclusion Criteria:\n\n1. Participants must give study-specific informed consent prior to enrollment\n2. Histologically confirmed adenocarcinoma of the prostate\n3. Participants meeting National Comprehensive Cancer Network (NCCN) intermediate-risk criteria\n4. Participants must be planning and medically able to undergo standard or moderate hypofractionated prostate-only EBRT (treatment and control group) and able to tolerate multiple transrectal ultrasound guided injections (treatment group only)\n5. 18 years of age or older\n6. Performance status must be Eastern Cooperative Oncology Group 0-2\n7. The following laboratory criteria must be met (treatment group only):\n\n   1. Aspartate aminotransferase (AST) \\\u003C 3 x upper limit of normal\n   2. Serum creatinine \\\u003C 2 mg\u002FdL\n   3. Calculated creatinine clearance \\> 30 mL\u002Fmin\n   4. White blood cells \\> 3000\u002Fmm3\n   5. Platelets \\>100,000\u002Fmm3\n\nExclusion Criteria:\n\n1. Active liver disease, including known cirrhosis or active hepatitis\n2. Participants on systemic corticosteroids (\\> 10 mg prednisone per day) or other immunosuppressive drugs\n3. Known HIV+ participants\n4. Regional lymph node involvement or distant metastases\n5. Participants planning to receive whole pelvic irradiation\n6. Other current malignancy (except squamous or basal cell skin cancers)\n7. Other serious co-morbid illness or compromised organ function that, in the opinion of the Investigator, would interfere with treatment or follow-up. For example, participants with diseases that preclude radiation therapy to the prostate such as severe prostatitis and inflammatory bowel disease.\n8. Prior treatment for prostate cancer except transurethral resection of the prostate (TURP). If prior TURP, participants must be deemed able to receive multiple intra-prostatic injections by the Investigator.\n9. Participants who had or plan to have orchiectomy as the form of hormonal ablation\n10. Known sensitivity or allergic reactions to acyclovir or valacyclovir (treatment group only)",{"count":92,"type":21},45,"INTERVENTIONAL",[95],"PHASE2","Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).",[26,58],[99,100,54,101],"Biomarkers","Viral Shedding","Aglatimagene Besadenovec","2026-03-19",{"date":104,"type":33},"2026-03-20",{"date":106,"type":33},"2025-10-30",{"date":108,"type":21},"2026-08",{"name":110,"class":111},"Candel Therapeutics, Inc.","INDUSTRY",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":93,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100602989","two-fraction-proton-therapy-with-mri-guidance-for-prostate-cancer-a-phase-ii-trial-100602989","NCT07130682","Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial","2-fraction Stereotactic Body Proton Therapy (SBPT) With Magnetic Resonance Imaging (MRI) Guidance in Localized Prostate Cancer: A Single-arm Phase II Non-randomized Trial","PT2","Inclusion Criteria:\n\n* Men aged \\\u003C 18 years with histologically confirmed low- or intermediate-risk prostate cancer per NCCN guidelines\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2\n* Ability to undergo magnetic resonance imaging (MRI) simulation scans without absolute contraindications, such as cardiac implantable electronic devices\n* Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease or other cancers (except prostate cancer)\n* Prior pelvic radiotherapy, chemotherapy, radical prostatectomy, cryosurgery, or focal therapy (e.g. high-intensity focused ultrasound \\[HIFU\\]) for prostate cancer\n* History of bladder neck or urethral stricture\n* Transurethral resection of the prostate (TURP) \\\u003C 8 weeks prior to SBPT\n* Prostate volume \\> 100cc on MRI\n* Unilateral or bilateral hip replacements\n* Nodal or distant metastases, as indicated by computed tomography (CT), MRI, or prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans\n* Previous androgen deprivation therapy (ADT) lasting more than 6 months",{"count":121,"type":21},35,[123],"NA","This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation. However, it is expensive and not easily accessible for many patients. To make it more affordable and accessible, this study is testing whether 2 fractions of stereotactic body proton therapy (SBPT) can be as safe and effective as the standard 5 sessions.",[26],[127,128,129,130],"Proton Therapy","Clinician reported outcome","patient reported outcome","low or intermediate risk prostate cancer","2026-03-13",{"date":133,"type":33},"2026-03-16",{"date":135,"type":33},"2025-09-01",{"date":137,"type":21},"2033-06-02",{"name":139,"class":111},"Hong Kong Sanatorium & Hospital",1,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":93,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":140},"100617984","phase-2-hypofractionated-radiotherapy-with-a-focal-microboost-for-high-risk-and-locally-advanced-prostate-cancer-100617984","NCT07325721","Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Biologically male patients aged 18 years and older.\n4. Ability to receive pelvic radiotherapy and be willing to adhere to the protocol regimen.\n5. Previously untreated prostate cancer (with cytotoxic chemotherapy, cryotherapy, ablative treatment, surgical or radiation therapy). Prior transurethral resection of prostate (TURP) is permitted if 90 days or more prior to the start of radiotherapy.\n6. Localized or locally advanced prostate cancer meeting NCCN criteria for high risk, very high risk or non-metastatic, pelvic lymph node positive defined as having at least one or more of the following:\n\n   1. PSA \\>20 ng\u002FmL prior to starting ADT.\n   2. cT3a-T4 by digital exam or imaging.\n   3. Gleason score of 8-10 (grade group 4 or 5).\n   4. Staged as N1M0 by the treating investigator (pelvic lymph node positive, below the aortic bifurcation) based on soft tissue imaging within 120 days prior to registration (may include CT, MRI or PSMA PET\u002FCT, of fluciclovine choline PET\u002FCT).\n7. History and physical exam within 120 days prior to registration.\n8. ECOG performance status 0-2.\n9. Be able to undergo MRI of the prostate and\u002For pelvis as a component of RT planning.\n10. Have at least one MRI visible target for microboost (PI-RADS≥ 4 version 2.0).\n11. Bone and soft tissue imaging as clinically indicated for staging within 120 days prior to registration.\n12. For males: use of condoms or other methods to ensure effective contraception with partner during radiation and for six months after completion of radiation.\n13. Adequate hematologic function within 120 days prior to registration as defined by:\n\n    1. hemoglobin \\>=9.0 g\u002FdL independent of transfusion, and\n    2. platelet count \\>= 100,000 x 10 \\^9\u002Fmicroliter independent of transfusion.\n14. Adequate hepatic function within 120 days prior to registration defined as total bilirubin \\\u003C2 x institutional upper limits of normal (ULN is 1.2 mg\u002FdL). If labs are done at outside institution, total bilirubin should be \\\u003C2.4.\n15. Agreeable and eligible to receive long term (defined as 12-36 months) ADT as a standard component of prostate cancer therapy.\n\nExclusion Criteria:\n\n* 1\\. Concurrent use of testosterone supplementation unless discontinued by time of registration.\n\n  2\\. Definitive radiologic evidence of metastatic disease outside of the pelvic nodes on conventional imaging (bone scan, CT scan, MRI).\n\n  3\\. Prior pelvic radiotherapy. 4. Pre-existing conditions or overall health status which disqualifies the patient from curative intent-RT. Patients with life expectancy less than 5 years are not eligible.\n\n  5\\. Treatment with another investigational prostate cancer therapy within 12 months.\n\n  6\\. Prior total prostatectomy, cryotherapy, high-intensity focused ultrasound, irreversible electroporation, MRI ablation, laser ablation, transurethral ultrasound ablation, aquablation directed towards the prostate for any prostate disease or condition.\n\n  7\\. Prior or concurrent invasive pelvic malignancy (except non-melanomatous skin cancer) or lymphomatous or hematogenous malignancy, unless disease free for a minimum of 5 years.\n\n  8\\. Any condition that, in the opinion of the investigator, would preclude participation in this study.\n\n  9\\. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 90 days prior to registration.\n\n  10\\. Inability to undergo implantation of gold fiducial markers or rectal spacer gel.\n\n  11\\. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.",{"count":148,"type":21},46,[95],"This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two emerging radiation treatment techniques (hypofractionated radiotherapy and microboost technique). Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. There is optional banking of blood and prostate biopsy tissue which will not require extra biopsies. Participation in this study is anticipated to last approximately 6 weeks with follow up every three months for two years then twice yearly for years 3-5.",[54,26],[153,154,155],"Prostate cancer","Microboost","hypofractionated","2026-02-03",{"date":158,"type":33},"2026-02-05",{"date":160,"type":33},"2026-02-02",{"date":162,"type":21},"2034-01-01",{"name":164,"class":40},"Medical University of South Carolina",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100603087","immune-biomarkers-in-prostate-cancer-patients-treated-with-brachytherapy-100603087","NCT07131956","Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy","Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (ImmunBioProBrachy)","Inclusion Criteria Arm 1:\n\n* Primary treatment with I-125 seeds or HDR-BT\n* No previous treatment for prostate cancer\n* Age ≥ 18 years\n\nInclusion Criteria Arm 2:\n\n* HDR- or PDR-BT\n* No radiation therapy within three months before salvage treatment\n* Complete documentation available on previous treatment for prostate cancer\n* No history of prostatectomy\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Pre-existent auto-immune disease\n* patients under bloodthinning medication\n* substance abuse",{"count":173,"type":21},200,"Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.",[55,176,26,177],"Prostate Cancer Patients Who Have Brachytherapy Seed Implant","Prostate Cancer Recurrent",[179,180,181],"Immune-profiling in prostate cancer patients","brachytherapy for prostate cancer","interstitial brachytherapy for prostate cancer","2025-11-17",{"date":184,"type":33},"2025-11-18",{"date":186,"type":21},"2025-12",{"date":188,"type":21},"2028-07-31",{"name":190,"class":40},"University of Erlangen-Nürnberg Medical School",3,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":93,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100566328","reminder-app-to-optimize-bladder-filling-during-radiotherapy-for-prostate-cancer-100566328","NCT06653751","Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer","A REminder App to Optimize Bladder FILLing During Radiotherapy of Patients With Prostate CAncer","REFILL-PAC","Inclusion Criteria:\n\n1. Histologically proven high-risk prostate cancer\n2. Indication for definitive normo-fractionated radiotherapy\n3. Possession of a smart phone and the ability to use it\n4. Bladder volume at CT-simulation \\\u003C200 ml\n5. Male gender\n6. Age ≥18 years\n7. Written informed consent\n8. Capacity of the patient to contract\n\nExclusion Criteria:\n\n1. Radiotherapy of pelvic lymph nodes\n2. Expected non-compliance",{"count":201,"type":21},28,[123],"The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes \\\u003C200 ml during the radiotherapy course and to demonstrate that this number is lower than without using an app (historical control group).",[26],[206,207,208],"High-risk prostate cancer","Radiotherapy","Mobile application","NOT_YET_RECRUITING","2025-06-17",{"date":212,"type":33},"2025-06-22",{"date":214,"type":21},"2025-07-01",{"date":216,"type":21},"2026-10-31",{"name":218,"class":40},"University Hospital Schleswig-Holstein",5,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":93,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100576347","a-reminder-app-to-optimize-bladder-filling-in-patients-with-prostate-cancer-receiving-hypo-fractionated-radiotherapy-100576347","NCT06784115","A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy","A REminder App to Optimize Bladder FILLing in Patients with ProstAte Cancer Receiving HYPO-fractionated Radiotherapy","REFILLPAC-HYPO","Inclusion Criteria:\n\n1. Histologically proven prostate cancer\n2. Indication for definitive HF-RT\n3. Possession of and ability to use a smartphone\n4. Bladder volume at CT-simulation \\\u003C200 ml\n5. Male gender\n6. Age ≥18 years\n7. Written informed consent\n8. Capacity of the patient to contract\n\nExclusion Criteria:\n\n1. Radiotherapy of pelvic lymph nodes\n2. Expected non-compliance",{"count":229,"type":21},27,[123],"The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes \\\u003C200 ml during the HF-RT course and to demonstrate that this number is lower than without using an app (historical control group).",[26],[234,235,236,237,238],"prostate cancer","radiotherapy","hypofractionation","mobile application","bladder filling","2025-01-17",{"date":241,"type":33},"2025-01-20",{"date":243,"type":21},"2025-02-15",{"date":245,"type":21},"2027-01-31",{"name":218,"class":40},4]